Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Cytogenetics in multiple myeloma patients progressing into extramedullary disease.

Besse L, Sedlarikova L, Greslikova H, Kupska R, Almasi M, Penka M, Jelinek T, Pour L, Adam Z, Kuglik P, Krejci M, Hajek R, Sevcikova S.

Eur J Haematol. 2016 Jul;97(1):93-100. doi: 10.1111/ejh.12688. Epub 2015 Oct 19.

PMID:
26432667
2.

Genome-wide screening of cytogenetic abnormalities in multiple myeloma patients using array-CGH technique: a Czech multicenter experience.

Smetana J, Frohlich J, Zaoralova R, Vallova V, Greslikova H, Kupska R, Nemec P, Mikulasova A, Almasi M, Pour L, Adam Z, Sandecka V, Zahradová L, Hajek R, Kuglik P.

Biomed Res Int. 2014;2014:209670. doi: 10.1155/2014/209670. Epub 2014 Jun 2.

3.

Nestin expression throughout multistep pathogenesis of multiple myeloma.

Svachova H, Kryukov F, Kryukova E, Sevcikova S, Nemec P, Greslikova H, Rihova L, Kubiczkova L, Hajek R.

Br J Haematol. 2014 Mar;164(5):701-9. doi: 10.1111/bjh.12689. Epub 2013 Dec 16.

PMID:
24329895
4.

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance.

Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Nekvindova J, Radova L, Greslikova H, Kuglik P, Vetesnikova E, Pour L, Adam Z, Sevcikova S, Hajek R.

Haematologica. 2014 Mar;99(3):511-8. doi: 10.3324/haematol.2013.093500. Epub 2013 Nov 15.

5.

Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH.

Smetana J, Dementyeva E, Kryukov F, Nemec P, Greslikova H, Kupska R, Mikulasova A, Ihnatova I, Hajek R, Kuglik P.

Neoplasma. 2014;61(1):48-55.

PMID:
24195508
6.

Incidence of cytogenetic aberrations in two B lineage subpopulations in multiple myeloma patients analyzed by combination of whole-genome profiling and FISH.

Smetana J, Dementyeva E, Kryukov F, Nemec P, Greslikova H, Kupska R, Mikulasova A, Ihnatova I, Hajek R, Kuglik P.

Neoplasma. 2013 Sep 20. doi: 10.4149/neo_2014_008. [Epub ahead of print]

PMID:
24050549
7.

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse.

Pour L, Sevcikova S, Greslikova H, Kupska R, Majkova P, Zahradova L, Sandecka V, Adam Z, Krejci M, Kuglik P, Hajek R.

Haematologica. 2014 Feb;99(2):360-4. doi: 10.3324/haematol.2013.094409. Epub 2013 Sep 13.

8.

Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.

Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4.

PMID:
23291040
9.

Prognostic significance of morphological assessment of plasma cells in multiple myeloma.

Al-Sahmani M, Trnavska I, Sevcikova S, Antosova M, Antosova L, Kissova J, Adam Z, Pour L, Nemec P, Greslikova H, Krejci M, Zahradova L, Bulikova A, Penka M, Hajek R.

Neoplasma. 2011;58(6):554-60.

PMID:
21895410
10.

Negative prognostic significance of two or more cytogenetic abnormalities in multiple myeloma patients treated with autologous stem cell transplantation.

Greslikova H, Zaoralova R, Filkova H, Nemec P, Oltova A, Kupska R, Rudolecka P, Smetana J, Pour L, Zahradova L, Krejci M, Buchler T, Adam Z, Hajek R, Kuglik P.

Neoplasma. 2010;57(2):111-7.

PMID:
20099973
11.

Centrosome amplification as a possible marker of mitotic disruptions and cellular carcinogenesis in multiple myeloma.

Dementyeva E, Nemec P, Kryukov F, Muthu Raja KR, Smetana J, Zaoralova R, Greslikova H, Kupska R, Kuglik P, Hajek R.

Leuk Res. 2010 Aug;34(8):1007-11. doi: 10.1016/j.leukres.2009.12.018. Epub 2010 Jan 21.

PMID:
20096458
12.

Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

Nemec P, Zemanova Z, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R.

Biol Blood Marrow Transplant. 2010 Apr;16(4):548-54. doi: 10.1016/j.bbmt.2009.11.025. Epub 2010 Jan 18.

Supplemental Content

Loading ...
Support Center